

Genomic sequencing of colorectal adenocarcinomas identifies a recurrent *VTI1A-TCF7L2* fusion

Adam J Bass^{1-4,20}, Michael S Lawrence^{4,20}, Lear E Brace¹, Alex H Ramos^{1,4}, Yotam Drier⁵, Kristian Cibulskis⁴, Carrie Sougnez⁴, Douglas Voet⁴, Gordon Saksena⁴, Andrey Sivachenko⁴, Rui Jing⁴, Melissa Parkin⁴, Trevor Pugh^{1,4}, Roel G Verhaak^{1,4}, Nicolas Stransky⁴, Adam T Boutin¹, Jordi Barretina⁴, David B Solit⁶, Evi Vakiani⁷, Wenlin Shao⁸, Yuji Mishina⁸, Markus Warmuth⁸, Jose Jimenez⁹, Derek Y Chiang¹⁰, Sabina Signoretti^{11,12}, William G Kaelin Jr^{1,2}, Nicole Spardy¹, William C Hahn¹⁻⁴, Yujin Hoshida⁴, Shuji Ogino^{1,11-13}, Ronald A DePinho^{1,2,14,15}, Lynda Chin^{1,4,15,16}, Levi A Garraway¹⁻⁴, Charles S Fuchs^{1,2,13}, Jose Baselga^{9,17}, Josep Taberero⁹, Stacey Gabriel⁴, Eric S Lander^{4,18,19}, Gad Getz⁴ & Matthew Meyerson^{1,3,4,11}

Prior studies have identified recurrent oncogenic mutations in colorectal adenocarcinoma¹ and have surveyed exons of protein-coding genes for mutations in 11 affected individuals^{2,3}. Here we report whole-genome sequencing from nine individuals with colorectal cancer, including primary colorectal tumors and matched adjacent non-tumor tissues, at an average of 30.7× and 31.9× coverage, respectively. We identify an average of 75 somatic rearrangements per tumor, including complex networks of translocations between pairs of chromosomes. Eleven rearrangements encode predicted in-frame fusion proteins, including a fusion of *VTI1A* and *TCF7L2* found in 3 out of 97 colorectal cancers. Although *TCF7L2* encodes TCF4, which cooperates with β -catenin⁴ in colorectal carcinogenesis^{5,6}, the fusion lacks the TCF4 β -catenin-binding domain. We found a colorectal carcinoma cell line harboring the fusion gene to be dependent on *VTI1A-TCF7L2* for anchorage-independent growth using RNA interference-mediated knockdown. This study shows previously unidentified levels of genomic rearrangements in colorectal carcinoma that can lead to essential gene fusions and other oncogenic events.

Colorectal cancer has served as a model to understand the progressive acquisition of oncogenic mutations in genes and pathways such as *APC*, *CTNBN1*, *TP53*, *RAS* genes and TGF- β signaling^{1,7}. Exome-wide sequencing has recently identified additional recurrent mutations

that may contribute to carcinogenesis^{2,3}. Further, genomic studies of colorectal cancer have detailed subgroups of tumors characterized by chromosomal instability (~60–70%), or by a high degree of microsatellite instability, often associated with hereditary or sporadic mismatch repair deficiency (~15%), with additional cases falling between these classes^{7,8}.

We sequenced the genomes of nine colorectal cancers and paired non-neoplastic tissue controls (Table 1). Tumors were resected before administration of chemotherapy or radiation and were selected for sequencing based upon a pathology-estimated purity of >70%. We used SNP arrays to confirm tumor purity and inferred ploidy and to select samples with copy-number alterations suggestive of a chromosomal-instability phenotype. We whole-genome sequenced these samples with paired 101-base reads with an average of 30.7× sequence coverage of the tumor genomes and 31.9× coverage of the germline (Table 1). We were able to reliably call mutations at ~83% of bases (with a range of 78–87%) based on the ability to uniquely align sequence reads and obtain $\geq 14\times$ coverage in the tumor and $\geq 8\times$ coverage in the germline.

These cases revealed frequent alterations in both sequence and genomic structure. Using the MuTect and Indelocator algorithms⁹⁻¹¹, we called 137,968 candidate somatic mutations across the nine samples. To evaluate our mutation calling, we validated candidate mutations predicted to cause non-synonymous substitutions or insertions-deletions in protein-coding sequences (Supplementary Tables 1 and 2).

¹Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. ²Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA. ³Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. ⁴Broad Institute, Cambridge, Massachusetts, USA. ⁵Department of Physics of Complex Systems, Weizmann Institute of Science, Rehovot, Israel. ⁶Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York, USA. ⁷Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA. ⁸Novartis Institute of Biomedical Research, Cambridge, Massachusetts, USA. ⁹Department of Medical Oncology, Hospital Vall d'Hebron, Passeig Vall d'Hebron, Barcelona, Spain. ¹⁰Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. ¹¹Department of Pathology, Harvard Medical School, Boston, Massachusetts, USA. ¹²Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA. ¹³Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA. ¹⁴Department of Genetics, Harvard Medical School, Boston, Massachusetts, USA. ¹⁵Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. ¹⁶Department of Dermatology, Harvard Medical School, Boston, Massachusetts, USA. ¹⁷Division of Hematology and Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA. ¹⁸Massachusetts Institute of Technology, Cambridge, Massachusetts, USA. ¹⁹Whitehead Institute for Biomedical Research, Cambridge, Massachusetts, USA. ²⁰These authors contributed equally to this work. Correspondence should be addressed to G.G. (gadget@broadinstitute.org) or M.M. (matthew_meyerson@dfci.harvard.edu).

Received 29 March; accepted 11 August; published online 4 September 2011; doi:10.1038/ng.936

Table 1 Characteristics of colorectal tumors used in whole-genome sequencing and summary of sequencing results from each tumor DNA

Individual	Stage	Pathologic purity estimate	Computational purity estimate	Computational ploidy estimate	Tumor coverage	Normal coverage	Genomic mutations	Mutations per Mb	Non-silent coding mutations	Rearrangements
CRC-1	I	90	83.7	2.02	27.3	24.1	10,445	4.0	70	24
CRC-2	I	90	79.9	2.14	31.1	31.1	10,561	4.1	47	5
CRC-3	III	80	53.7	2.1	35.1	34.4	13,572	5.1	89	124
CRC-4	III	80	92.7	2.35	34.7	40.3	13,883	5.5	89	92
CRC-5	IV	70	83.7	3.37	29.4	30.2	17,315	6.7	76	83
CRC-6	II	80	58.4	2.67	29.6	33.0	10,296	4.0	30	75
CRC-7	II	75	95.1	2.91	30.5	29.3	15,884	6.2	76	22
CRC-8	II	70	82.5	3.33	28.5	30.1	19,931	7.7	88	68
CRC-9	II	80	80.2	1.77	30.5	34.6	26,081	9.8	147	182
Average					30.7	31.9	15,330	5.9	79	75
Total							137,968		712	675

Among these 712 candidates, 521 could be tested by mass spectrometric genotyping, and we validated 84% (439) as somatic alterations. Notably, genotyping validation rates were ~95% (292 out of 308) for mutations at a high allele fraction (>0.33). The higher validation rate for higher allele fraction mutations is consistent with the possibility that mass spectrometric techniques require a minimum threshold for variant allele detection.

The whole-genome sequence also allows us to evaluate the overall features of somatic mutations. Using all candidate mutations, we calculated an overall mutation rate of ~5.9 per Mb with a range of 4.0–9.8 mutations per Mb relative to a haploid genome (Table 1). Assuming that as many as 16% of these events are false positives, this would predict a mutation rate of ~5 mutations per Mb. This mutation rate exceeds the previously estimated rate of 1.2 mutations

per Mb derived from a sequencing tiling array³, likely reflecting the greater sensitivity of massively parallel sequencing. The mutation rate is somewhat higher in intergenic regions (6.7 per Mb) than in intronic and exonic sequences (4.8 per Mb and 4.2 per Mb, respectively), presumably because of selection pressure and transcription-coupled repair^{12,13}. Within coding sequences, the rate of non-synonymous mutations that we saw, 3.1 per Mb, resembles the 2.8 per Mb rate seen from Sanger resequencing².

The base context of the somatic mutations is consistent with previous reports that colorectal cancers show a strong predilection for C>T transitions at CpG dinucleotides^{2,3}; we found an increase in mutations at CpG sites (37–72 per million sites) compared to all mutations other than CpG transitions (3.2–8.5 per Mb) (Supplementary Fig. 1). Inspection of consensus loci used to test for sporadic mismatch repair deficiency¹⁴ showed no signs of microsatellite instability. We observed low rates of insertions-deletions within coding regions (0–5 events per tumor).

Analysis of the non-synonymous coding somatic substitutions and small insertions-deletions identified 24 genes with such mutations in two or more tumors (Supplementary Table 3). Although the small sample set provides inadequate power to detect recurrent mutations, *KRAS*, *APC* and *TP53* nonetheless scored as significant relative to the background mutation rate. Indeed, we noted mutations in *KRAS*, *APC* and *TP53* in five, seven and six individuals' tumors, respectively (Supplementary Table 2). We found other genes with known colorectal cancer mutations, such as *NRAS*, *SMAD4*, *PIK3CA* and *FBXW7*, to be mutated here, but these genes' rates of mutation did not





Figure 1 DNA structural rearrangements and copy number alterations detected in the nine colorectal tumors displayed as CIRCOS plots³³. Chromosomes are arranged circularly end-to-end with each chromosome's cytobands marked in the outer ring. The inner ring displays copy number data inferred from whole-genome sequencing with blue indicating losses and red indicating gains. Within the circle, rearrangements are shown as arcs with intrachromosomal events in green and interchromosomal translocations in purple.

Figure 2 Complex rearrangements between chromosome pairs in two colorectal carcinomas. The central portion of the figure contains copy-number profiles across all chromosomes with the chromosome identity labeled across the x axis and the scale for copy-number ratio (\log_2) depicted on the y axis of each plot. The upper plot shows the tumor CRC-4, and the lower plot shows the copy-number profile for CRC-6, with the black dots marking the copy-number ratio inferred along each locus across the genome. The upper inset boxes show detailed views of the copy numbers and rearrangements for chromosomes 8 (dark blue) and 20 (ochre) for CRC-4 with the centromere labeled as a purple circle. Rearrangements detected by dRanger are shown in green (intrachromosomal) and purple (interchromosomal). The lower inset boxes show detailed copy-number and rearrangement images for CRC-6, with inset boxes showing chromosome 5 (red) and 11 (gray), with lines marking positions of genomic rearrangements.



reach statistical significance given the small sample set. Large sequencing projects will be needed to identify a fuller set of genes with significant recurrent mutations; such projects are now being carried out under The Cancer Genome Atlas (see URLs).

Whole-genome sequencing enables detailed study of the nature of chromosomal rearrangements. Using our algorithm (dRanger^{10,11}), we identified 675 candidate somatic rearrangements across the nine tumors (mean, 75; range 5–182; **Fig. 1** and **Supplementary Table 4**) by identifying instances where multiple paired reads map to distinct genomic loci or with incorrect orientations. To assess the accuracy of these findings, we tested 331 candidate somatic rearrangements by performing PCR across the putative junction in tumor and germline DNA; we pooled the PCR products and pyrosequenced them. We confirmed 92% of the calls as true somatic rearrangements; we found four calls (~1%) to be germline rearrangements and removed

them from further analysis, and the remaining 22 calls (~7%) failed to yield PCR products in either tumor or germline DNA. Tumors with more somatic coding mutations also harbored more rearrangements ($R^2 = 0.55$).

The majority (82%) of predicted rearrangements are intrachromosomal, and among these events, roughly half (46%) involve 'long-range' events connecting chromosomal regions more than 1 Mb apart. We classified the short-range rearrangements, occurring at sub-Mb scales, as deletions (64%), tandem duplications (19%) and inversions (17%) based on an analysis of the paired-end sequences (**Supplementary Fig. 1**). We studied the sequence at the breakpoints in these rearrangements using pyrosequencing of PCR products spanning the junctions and also using identification in our sequencing of fusion sequences joining predicted rearrangements using the BreakPointer tool¹⁰. The junctions typically show significant microhomology of 1–6 bases and insertion of non-template DNA is uncommon (**Supplementary Fig. 1**), observations that are consistent with results reported in breast cancer¹⁵. Also consistent with prior reports, tandem duplications show a greater degree of microhomology¹⁵.

Three samples (CRC-3, CRC-4 and CRC-6) showed clustering of inter-chromosomal translocations, where a series of rearrangements leads to extensive regional shuffling of two to three distinct chromosomes through balanced translocations (**Fig. 1**). We saw networks of fusions between chromosomes 8 and 20 in CRC-4 and chromosomes 5 and 11 in CRC-6 (**Fig. 2**). Because most of these events do not involve regions of substantial copy-number alterations, they represent a variant of a pattern (termed chromothripsis¹⁶) involving alternating copy-number states induced by a single catastrophic complex genomic event. Our results show the potential for complex structural alterations to occur in regions of the genome that appear to be 'quiet' based on copy-number profiling.

We examined the specific genes affected by the genomic rearrangements. We found small deletions in well-known cancer-related genes, including a deletion that removed the first exon of *EGFR* in CRC-9 and a deletion removing the 3' section of *PTEN* in CRC-8. Twenty-six genes harbored breakpoints in multiple samples. The most frequently rearranged genes were *MACROD2*, *A2BP1*, *FHIT*

Table 2 Predicted in-frame fusion proteins detected by dRanger

Tumor	Fusion	Fusion Sites
CRC-3	<i>MED20</i> exon 2 to <i>PKHD1</i> exon 61	chr6:41,989,443 to chr6:51,716,875
CRC-3	<i>EYS</i> exon 40 to <i>PSS2</i> exon 2	chr6:64,543,886 to chr6:107,883,344
CRC-3	<i>CLIC5</i> exon 2 to <i>SCGN</i> exon 5	chr6:25,774,444 to chr6:46,056,110
CRC-4	<i>ZCCHC2</i> exon 8 to <i>DYM</i> exon 14	chr18:45,023,683 to chr18:58,380,361
CRC-5	<i>ZBP1</i> exon 5 to <i>SLC24A3</i> exon 3	chr20:19,298,150 to chr20:55,620,385
CRC-5	<i>BMP7</i> exon 1 to <i>MACROD2</i> exon 13	chr20:15,891,802 to chr20:55,255,653
CRC-6	<i>SPANXN3</i> exon 1 to <i>TEX11</i> exon 26	chrX:69,736,103 to chrX:142,429,599
CRC-6	<i>SAPS3</i> exon 10 to <i>CEP120</i> exon 20	chr5:122,715,537 to chr11:68,093,742
CRC-6	<i>RGMB</i> exon 2 to <i>ZFP91</i> exon 2	chr5:98,134,842 to chr11:58,106,127
CRC-9	<i>VTI1A</i> exon 3 to <i>TCF7L2</i> exon 4	chr10:114,220,869 to chr10:114,760,545
CRC-9	<i>FBXW11</i> exon 1 to <i>CAST</i> exon 26	chr5:96,131,900 to chr5:171,355,322




Figure 3 Recurrent gene fusion between *VTI1A* and *TCF7L2*. (a) The upper schematic depicts the positions of exons (vertical lines) within *VTI1A* and *TCF7L2*, which reside adjacent to each other on chromosome 10. The blowup displays the locations of discordant paired-end reads found in tumor CRC-9 for which one read (labeled in blue) is in an intron of *VTI1A* and the other read (labeled in red) is in an intron of *TCF7L2*. (b) The upper schematic depicts the structure of the predicted fusion transcript generated by the fusion. The presence of the exact reads spanning the fusion of the two introns (marked by lightning bolt) is depicted in the inset with regions of the reads corresponding to original *VTI1A* intron in blue and those of *TCF7L2* in red. (c) The protein domain structure of native *VTI1A* and *TCF4-TCF7L2*, including the two alternate C-terminal tails of TCF4, are shown. Below are the structures of the fusion protein encoded by the fusion of exon 3 of *VTI1A* to exon 4 of *TCF7L2* identified in CRC-9. Two variants of the fusion are shown as data from the NCI-H508 cell line and reveal that variants encoding both the full length (E-tail) and shorter (B-tail) C termini are both expressed (data not shown). (d) Measurement of the relative expression of the *VTI1A-TCF7L2* mRNA in NCI-H508 cells infected with one of two short hairpin RNA constructs targeting the fusion gene relative to expression in a cell infected with control vectors targeting *GFP*. (e) Anchorage-independent growth of the NCI-H508 cell line, which expresses *VTI1A-TCF7L2*, and negative control DLD-1 colorectal adenocarcinoma cells following RNA-interference-mediated knockdown of *VTI1A-TCF7L2* compared to control knockdown targeting *GFP*.

and *IMMP2L* (Supplementary Table 3), which span large genomic loci. Previous work has shown that such genes are frequently subject to focal deletions in cancer^{17,18}, possibly because of structural fragility. Notably, two samples, CRC-5 and CRC-7, contain chromosome 3:12 translocations in which distinct intergenic regions of chromosome 3 are fused to the first intron of the methyltransferase-encoding *PRMT8*. However, we identified no detectable *PRMT8* transcript in RNA from either of the two samples (data not shown).

We next sought to identify functional fusion genes. Such events have been previously seen in carcinomas from the lung¹⁹ and prostate²⁰, among others, but to our knowledge have not been reported in colon carcinomas. We found 11 rearrangements (2 interchromosomal and 9 intrachromosomal rearrangements) that could give rise to in-frame fusion transcripts (Table 2). By screening complementary DNA (cDNA) from a panel of 97 primary colorectal cancers, we found that one of these possible fusion transcripts is recurrently expressed. The initial observation, which occurred in CRC-9, involved an intrachromosomal fusion on chromosome 10, fusing the first three exons of *VTI1A*, which encodes a v-SNARE protein mediating fusion of intracellular vesicles within the Golgi complex²¹, to the fourth exon of the adjacent gene, *TCF7L2* (Fig. 3a–c). We found in-frame *VTI1A-TCF7L2* fusions in two additional cases and three of 97 total primary colorectal carcinomas (including the CRC-9 index case) (Supplementary Fig. 2).

The discovery of recurrent *VTI1A-TCF7L2* fusions is of particular interest. *TCF7L2* encodes a transcription factor, known as TCF4 and belonging to the TCF/LEF family, that dimerizes with β -catenin (encoded by *CTNNB1*) to activate and repress transcription of genes essential for proliferation and differentiation of intestinal epithelial cells²². *TCF7L2* is the most widely expressed member of the TCF/LEF family in colorectal cancer²³ and its expression is inversely associated with survival in colorectal cancer²⁴. Moreover, the inherited risk of colorectal cancer is affected by polymorphisms in *TCF7L2* (refs. 25,26) as well as by a polymorphism in an enhancer of *MYC* at which TCF4 and β -catenin cooperatively bind^{27,28}. Notably, *TCF7L2* is known to harbor somatic point mutations in colorectal

cancer^{2,3}. We additionally found a point mutation in CRC-5 affecting the splice-site at the 3' end of exon 10, which is the exon encoding the HMG-box DNA binding domain, that would likely be a deleterious mutation.

To test the functional importance of the *VTI1A-TCF7L2* fusion, we sought a cell line harboring this event. Because the fusion in CRC-9 is caused by a ~540-kb deletion between *VTI1A* and *TCF7L2*, we studied SNP array data from 38 colorectal cancer cell lines to search for a similar deletion. We found that the cell line NCI-H508 (Supplementary Fig. 2) carries such a deletion, and we showed the presence of an in-frame fusion transcript linking exon 2 of *VTI1A* to exon 5 of *TCF7L2*. We designed RNA-interference vectors targeting the sequence spanning the fusion. Two vectors that reduced the expression of the fusion mRNA by >70% as gauged by quantitative RT-PCR caused a dramatic reduction in the anchorage-independent growth of cells from NCI-H508 but not DLD-1, a colorectal cancer cell line that does not harbor the fusion gene (Fig. 3d,e). This result shows that the *VTI1A-TCF7L2* fusion plays a critical role in NCI-H508 cell growth.

The biochemical function of the *VTI1A-TCF7L2* fusion protein is unclear. The fusion omits the amino-terminal domain of TCF4, which binds β -catenin (Fig. 3c). For other members of the TCF/LEF family (but not for *TCF7L2*), isoforms omitting the amino-terminal domain occur naturally and yield dominant-negative proteins²⁹. However, we do not expect the *VTI1A-TCF7L2* fusion protein to act as a full dominant-negative protein because engineered dominant-negative TCF4 alleles have been shown to strongly inhibit proliferation of colorectal carcinoma cell lines³⁰. Given the omission of the β -catenin binding domain in this fusion gene, we initially hypothesized that this newly identified protein could enable β -catenin-independent activation of TCF4 and/or β -catenin targets. However, the three tumors harboring the fusion protein also carry mutations in *APC*, whose product suppresses β -catenin. (CRC-9 has one frameshift and one nonsense mutation in *APC*, the second tumor harbors a homozygous ~90-kb deletion within *APC*, and the third tumor has a p.Ala1247Val *APC* alteration). NCI-H508 is heterozygous for *APC* (carrying a hemizygous deletion) and carries

normal alleles at *CTNNB1*, which encodes β -catenin, yet is functionally dependent upon β -catenin (**Supplementary Fig. 2**).

These results suggest that *VTI1A-TCF7L2* is expressed in the setting of activated β -catenin and that NCI-H508 is dependent on both the fusion gene and β -catenin despite the deletion of the *VTI1A-TCF7L2* β -catenin binding domain. Studies will be needed to determine whether and how (i) the fusion gene interacts or interferes with the function of β -catenin and (ii) the addition of a section of an N-terminal SNARE domain affects function or localization. When coupled to the recent report of *TCF7L2* mutations in colorectal cancer and evidence that *TCF4* can also have tumor suppressive functions in colorectal neoplasia^{31,32}, these data suggest additional complexity regarding the function of β -catenin and its cooperating factors in colorectal cancer.

This report describes the first whole-genome sequencing study of colorectal cancer. Our results provide no evidence for high-frequency recurrent translocations, such as those that are seen in prostate adenocarcinoma²⁰. However, the discovery of the recurrent *VTI1A-TCF7L2* fusion in 3% of colorectal cancers shows that functionally important fusion events occur in this disease and suggest that further structural characterization will likely identify additional new recurrent rearrangements.

URLs. The Cancer Genome Atlas, <http://cancergenome.nih.gov/>; Broad-Novartis cell line encyclopedia database, <http://www.broadinstitute.org/ccle/home>; Broad Institute Picard Sequencing Pipeline, <http://picard.sourceforge.net/>.

METHODS

Methods and any associated references are available in the online version of the paper at <http://www.nature.com/naturegenetics/>.

Accession codes. Sequencing data from this paper are deposited into the dbGaP repository with the accession number phs000374.v1.p1. A list of all candidate mutations and more detailed information on mutation rates are available at <http://www.broadinstitute.org/~lawrence/crc/>.

Note: Supplementary information is available on the Nature Genetics website.

ACKNOWLEDGMENTS

We thank all members of the Biological Samples Platform and DNA Sequencing Platforms of the Broad Institute, without whose work this sequencing project could not have occurred, and R. Shivdasani and M. Freedman for helpful discussion. This work was supported by US National Institutes of Health grant K08CA134931 (A.J.B.), a GI SPORE Developmental Project Award (P50CA127003; M.M.) and the National Human Genome Research Institute (E.S.L.).

AUTHOR CONTRIBUTIONS

A.J.B., M.S.L., A.H.R., Y.D., K.C., A.S., T.P., R.J., D.V., G.S., R.G.V. and N. Stransky performed computational analysis. J. Barretina, J. Baselga, J.J., J.T., D.B.S., E.V., D.Y.C., W.G.K. and S.S. provided samples for analysis. A.J.B., L.E.B., Y.M. and W.S. performed laboratory experiments. A.T.B., Y.H., M.W., N.S., R.A.D., W.C.H., C.S.F. and S.O. provided expert guidance regarding the analysis. C.S., M.P., L.C., L.A.G., S.G. and E.S.L. supervised and designed the sequencing effort. A.J.B., M.S.L., E.S.L., G.G. and M.M. designed the study, analyzed the data and prepared the manuscript. All coauthors reviewed and commented on the manuscript.

COMPETING FINANCIAL INTERESTS

The authors declare competing financial interests: details accompany the full-text HTML version of the paper at <http://www.nature.com/naturegenetics/>.

Published online at <http://www.nature.com/naturegenetics/>.

Reprints and permissions information is available online at <http://www.nature.com/reprints/index.html>.

1. Fearon, E.R. & Vogelstein, B. A genetic model for colorectal tumorigenesis. *Cell* **61**, 759–767 (1990).
2. Sjöblom, T. *et al.* The consensus coding sequences of human breast and colorectal cancers. *Science* **314**, 268–274 (2006).
3. Wood, L.D. *et al.* The genomic landscapes of human breast and colorectal cancers. *Science* **318**, 1108–1113 (2007).
4. Clevers, H. Wnt/ β -Catenin signaling in development and disease. *Cell* **127**, 469–480 (2006).
5. Nishisho, I. *et al.* Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. *Science* **253**, 665–669 (1991).
6. Kinzler, K.W. *et al.* Identification of FAP locus genes from chromosome 5q21. *Science* **253**, 661–665 (1991).
7. Markowitz, S.D. & Bertagnolli, M.M. Molecular basis of colorectal cancer. *N. Engl. J. Med.* **361**, 2449–2460 (2009).
8. Ogino, S. & Goel, A. Molecular classification and correlates in colorectal cancer. *J. Mol. Diagn.* **10**, 13–27 (2008).
9. The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. *Nature* **474**, 609–615 (2011).
10. Berger, M.F. *et al.* The genomic complexity of primary human prostate cancer. *Nature* **470**, 214–220 (2011).
11. Chapman, M. *et al.* Initial genome sequencing and analysis of multiple myeloma. *Nature* **471**, 467–472 (2011).
12. Lee, W. *et al.* The mutation spectrum revealed by paired genome sequences from a lung cancer patient. *Nature* **465**, 473–477 (2010).
13. Pleasance, E.D. *et al.* A comprehensive catalogue of somatic mutations from a human cancer genome. *Nature* **463**, 191–196 (2010).
14. Boland, C.R. *et al.* A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. *Cancer Res.* **58**, 5248–5257 (1998).
15. Stephens, P.J. *et al.* Complex landscapes of somatic rearrangement in human breast cancer genomes. *Nature* **462**, 1005–1010 (2009).
16. Stephens, P.J. *et al.* Massive genomic rearrangement acquired in a single catastrophic event during cancer development. *Cell* **144**, 27–40 (2011).
17. Bignelli, G.R. *et al.* Signatures of mutation and selection in the cancer genome. *Nature* **463**, 893–898 (2010).
18. Beroukhim, R. *et al.* The landscape of somatic copy-number alteration across human cancers. *Nature* **463**, 899–905 (2010).
19. Soda, M. *et al.* Identification of the transforming *EML4-ALK* fusion gene in non-small cell lung cancer. *Nature* **448**, 561–566 (2007).
20. Tomlins, S.A. *et al.* Recurrent fusion of *TMPRSS2* and *ETS* transcription factor genes in prostate cancer. *Science* **310**, 644–648 (2005).
21. Kreykenbohm, V. *et al.* The SNAREs *vti1a* and *vti1b* have distinct localization and SNARE complex partners. *Eur. J. Cell Biol.* **81**, 273–280 (2002).
22. Waterman, M.L. Lymphoid enhancer factor/T cell factor expression in colorectal cancer. *Cancer Metastasis Rev.* **23**, 41–52 (2004).
23. Korinek, V. *et al.* Constitutive transcriptional activation by a β -Catenin-Tcf complex in *APC*^{-/-} colon carcinoma. *Science* **275**, 1784–1787 (1997).
24. Kriegl, L. *et al.* *LEF-1* and *TCF4* expression correlate inversely with survival in colorectal cancer. *J. Transl. Med.* **8**, 123 (2010).
25. Folsom, A.R. *et al.* Variation in *TCF7L2* and increased risk of colon cancer: the Atherosclerosis Risk in Communities (ARIC) Study. *Diabetes Care* **31**, 905–909 (2008).
26. Hazra, A. *et al.* Association of the *TCF7L2* polymorphism with colorectal cancer and adenoma risk. *Cancer Causes Control* **19**, 975–980 (2008).
27. Tuupanen, S. *et al.* The common colorectal cancer predisposition SNP rs6983267 at chromosome 8q24 confers potential to enhanced Wnt signaling. *Nat. Genet.* **41**, 885–890 (2009).
28. Pomerantz, M.M. *et al.* The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer. *Nat. Genet.* **41**, 882–884 (2009).
29. Roose, J. *et al.* Synergy between tumor suppressor APC and the β -Catenin-Tcf4 target Tcf1. *Science* **285**, 1923–1926 (1999).
30. Van de Wetering, M. *et al.* The β -Catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. *Cell* **111**, 241–250 (2002).
31. Tang, W. *et al.* A genome-wide RNAi screen for Wnt/ β -catenin pathway components identifies unexpected roles for TCF transcription factors in cancer. *Proc. Natl. Acad. Sci. USA* **105**, 9697–9702 (2008).
32. Angus-Hill, M.L. *et al.* T-cell factor 4 functions as a tumor suppressor whose disruption modulates colon cell proliferation and tumorigenesis. *Proc. Natl. Acad. Sci. USA* **108**, 4914–4919 (2011).
33. Krzywinski, M. *et al.* Circos: an informative aesthetic for comparative genomics. *Genome Res.* **19**, 1639–1645 (2009).

ONLINE METHODS

Sample selection and preparation. Colorectal adenocarcinoma and matched adjacent non-cancerous colon from affected individuals not previously treated with chemotherapy or radiation were collected and frozen at the time of surgery under institutional review board-approved protocols (each collection was approved by the local institutional review board of the center where surgery was performed. Subsequently, the Broad Institute's institutional review board reviewed the local institutional review board approvals and consent documents to approve the use of samples for sequencing see **Supplementary Note**). Tumors were reviewed to confirm the diagnosis and to estimate tumor content. Nine tumors with an estimated tumor content of at least 70% were selected. DNA was extracted using standard techniques.

Tumor DNA samples were processed and hybridized to Affymetrix SNP arrays for copy number analysis. Six of the samples had been evaluated using the STY I array³⁴. The remaining tumors were evaluated with SNP6 arrays. Array data were processed and segmented using standard approaches to identify copy number aberrations³⁵. SNP array data were further analyzed using the tool ABSOLUTE (S.L. Carter, M. Meyerson & G. Getz, personal communication) to infer the tumor purity and ploidy^{10,11}. Tumors were required to have either an estimated purity of 50% or an allelic ratio of 0.25.

Whole-genome sequencing. Sequencing was performed using Illumina GA-II¹⁰. Briefly, 1–3 micrograms of DNA from each sample were used to prepare the sequencing library through shearing of the DNA followed by ligation of sequencing adaptors. Each sample was sequenced on multiple Illumina flow cells with paired 101-bp reads to achieve ~30× genomic coverage.

Sequence data processing. Raw data were processed using the 'Picard' pipeline, which was developed at the Broad Institute⁹. As described previously^{10,11}, the BAM file for each tumor and germline sample (hg18) were generated and imported into the Firehose analysis pipeline¹¹. This system has been designed to house input files containing sequence data and then organize the execution of multiple analytic tools to identify somatic aberrations. Copy-number analysis of sequence data was performed as described previously using whole-genome sequencing data³⁶.

Calculation of sequence coverage, mutation calling and significance analysis. We compared the concordance of sequencing calls and SNP genotypes, which is one metric of sequencing coverage for mutation detection³⁷. From the Affymetrix data in tumors, we extracted the high-confidence heterozygous genotype calls and compared these to the genotypes extracted from the Illumina data. We identified concordance rates of 94–99% in the tumors and 97–99% in the matched germline DNA samples. We further evaluated the fraction of all bases suitable for mutation calling whereby a base is defined as covered if at least 14 and 8 reads overlapped the base in the tumor and in the germline sequencing, respectively. Those covered regions were subsequently evaluated for single nucleotide variations using MuTect^{9–11}. Passing single nucleotide variants found within coding areas of the genome were annotated for their predicted effect on the amino acid sequence and on exon splicing. Coding areas were evaluated for insertion-deletion events using the Indelocator algorithm^{10,11}.

From the candidate somatic mutations and insertions-deletions, predicted non-synonymous coding alterations were validated in both tumor and matched germline DNA using multiplexed mass spectrometric genotyping^{10,35}. Among 712 total candidates, genotyping assays could be designed against and yielded interpretable data for a subset (521 candidates), producing a validation rate of 84%. Notably, all assays from CRC-5 failed in PCR because of degradation of the DNA from this tumor occurring after Illumina library construction and sequencing; these assays were removed from evaluation of the validation rates. Candidate mutations identified in the non-tumor DNA were considered to be germline polymorphisms and were removed from analysis. Given the possibility for false negative results from our validation experiments (in particular, the known lack of sensitivity of multiplexed mass spectrometric genotyping in the case of mutations present at low allele fraction), to maximize the potential for discovery of new events, we included in our analysis all 699 mutations not invalidated as germline. As shown in **Supplementary Table 1**, mutations are annotated as to those that were tested and validated, tested and not validated and those not tested because of assay failure.

After all coding single nucleotide variants and insertion-deletions were identified, the MutSig algorithm was used to identify genes subject to recurrent non-synonymous genetic alterations at a rate above that which would be expected by chance^{10,11}. The calculated likelihood for a certain number of mutations to occur by chance takes into account the base context of the mutations and the rates of those events in the set of genomes. A false discovery rate (or *q* value) of 0.05 was used as the cutoff to define significance. All mutation rates are calculated relative to the theoretical underlying haploid genome.

Identification of rearrangements. The dRanger algorithm^{10,11} was used to identify genomic rearrangements by identifying instances where the two read pairs map to distinct regions or map in such a manner that suggests another structural event, such as an inversion. All such candidate lesions were then queried in both the matched germline genome and a panel of non-tumor genomes to remove events detected in germline genomes. The final scorings of these somatic reads were then calculated by multiplying the number of supporting read pairs by the estimated 'quality' of the candidate rearrangement, a measure ranging from 0 to 1 that takes into account the alignability of the two regions joined by the putative rearrangement and also the chance of seeing such a read pair given the libraries' fragment-size distributions. Those events with resulting scores ≥ 3 (and thus seen in at least three read pairs) were included in this analysis. Validation of rearrangements was performed by PCR using primers spanning the predicted breakpoints as described previously¹⁰. PCR products were sequenced on the 454 pyrosequencing platform with DNA from tumor and matched normal samples to validate the presence and somatic status of candidate events. For those events failing validation in the first set of PCRs, a follow-up round of PCR and pyrosequencing was performed with two sets of primers per candidate rearrangement.

To identify the DNA sequence of the actual fusion between two genomic loci, the BreakPointer algorithm was employed. BreakPointer searches for read pairs where one read is mapped entirely on one side of the breakpoint and the pair mate is partly mapped on the breakpoint or failed to align anywhere. It is expected that many of these reads span the actual fusion point. These unmapped reads are subjected to a modified Smith-Waterman alignment procedure with the ability to jump between the two reference sequences at the most fitting point (Drier, Y. *et al.*, manuscript in preparation). From these breakpoints, the degree of base overlap or microhomology of the two adjoined sequences was calculated, and insertions of non-template DNA were identified. BreakPointer analysis of the Illumina data was able to predict fusion sites of 214 rearrangements, of which 200 (93.5%) were validated by pyrosequencing data.

Validation of the *VTI1A-TCF7L2* fusion transcript. The NCI-H508 cell line was identified from SNP-array-derived copy number from a collection of 38 colorectal cancer cell lines in the Broad-Novartis Cell Line Encyclopedia. RNA prepared from samples of fresh-frozen colorectal adenocarcinomas or, in the case of the NCI-H508 cell line, a fresh cell pellet, were used for cDNA synthesis with the QIAGEN QuantiTect kit. cDNA quality was assessed by the ability to PCR amplify the *GAPDH* transcript. Passing cDNA was evaluated with a first round of PCR using primers to the 5' untranslated region of *VTI1A* and exon 6 of *TCF7L2* and then nested PCR using primers from the first exon of *VTI1A* and exon 5 of *TCF7L2* (the primers used are listed in **Supplementary Table 5**). Bands were gel purified, cloned (TOPO TA Cloning; Invitrogen) and sequenced to validate the presence and frame of fusion.

RNA-interference experiments. Using the sequence of the junction between exon 2 of *VTI1A* and exon 5 of *TCF7L2* from the NCI-H508 cell line, shRNA vectors containing 21-base seed sequences uniquely homologous to the fusion sequence were generated and cloned into the pLKO lentiviral vector³⁸. From these vectors and a control shRNA vector targeting GFP, the lentivirus was produced and used to infect the NCI-508 cell lines³⁹. Following puromycin selection, RNA was extracted for cDNA synthesis. Real-time PCR (using two distinct primer sets quantifying the *VTI1A-TCF7L2* fusion; **Supplementary Table 5**) was used to quantitate the expression of *VTI1A-TCF7L2* mRNA relative to expression of a *GAPDH* control. Two shRNAs, which were able to induce

significant (~70%) knockdown, were selected for further experiments. These vectors are labeled shFusionA (target GAAGCGAAAGAACTGTCTAAC) and shFusionB (target GCGAAAGAACTGTCTACAAA). Following new infections of these viruses and shGFP into NCI-H508 and DLD-1 cell lines, both cultured in Roswell Park Memorial Institute medium (RPMI) with 10% FBS with glutamine and penicillin streptomycin, cells were selected with puromycin and then plated into soft agar as previously described to evaluate anchorage-independent growth³⁹.

For knockdown of *CTNNB1* in the NCI-H508 cells, two *CTNNB1* shRNA constructs that had been cloned into a doxycycline-inducible version of the pLKO.1 vector were used. The two vectors contained sequencing targeting the following sites: sh35: CCCTAGCCTTGCTTGTAATAA and sh36: GGACAAGCCACAAGATTACAA, with knockdown verified by real-time PCR (Applied Biosystems Hs00170025_m1). Cells infected with NTC (non-targeting control) or *CTNNB1* shRNA were grown in the presence or

absence of 20 ng/ml doxycycline for 48 h. To quantitate knockdown, RNA from shRNA-infected cells was quantified with real-time PCR. Cells were then placed into soft agar in the presence or absence of 20 ng/ml doxycycline to assess colony formation.

34. Firestein, R. *et al.* *CDK8* is a colorectal cancer oncogene that regulates β -catenin activity. *Nature* **455**, 547–551 (2008).
35. The Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. *Nature* **455**, 1061–1068 (2008).
36. Chiang, D.Y. *et al.* High-resolution mapping of copy-number alterations with massively parallel sequencing. *Nat. Methods* **6**, 99–103 (2009).
37. Ley, T.J. *et al.* DNA sequence of a cytogenetically normal acute myeloid leukemia genome. *Nature* **456**, 66–72 (2008).
38. Moffat, J. *et al.* A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. *Cell* **124**, 1283–1298 (2006).
39. Bass, A.J. *et al.* *SOX2* is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinoma. *Nat. Genet.* **41**, 1238–1242 (2009).